Core Viewpoint - The company, Longshen Rongfa, has received a medical device registration certificate for its blood dialysis concentrate solution from the National Medical Products Administration, indicating a significant regulatory milestone for the company in the healthcare sector [1] Group 1: Product Details - The blood dialysis concentrate solution consists of two parts: A concentrate and B concentrate [1] - A concentrate includes sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2·2H2O), magnesium chloride (MgCl2·6H2O), acetic acid (CH3COOH), and dialysis water [1] - B concentrate is composed of sodium bicarbonate (NaHCO3) and dialysis water [1] Group 2: Application Scope - The product is intended for use in the treatment of acute renal failure and chronic renal failure through blood dialysis [1]

Core Viewpoint - The company, Longshen Rongfa, has received a medical device registration certificate for its blood dialysis concentrate from the National Medical Products Administration, indicating a significant regulatory milestone for its product line [1] Group 1: Product Details - The blood dialysis concentrate consists of two parts: A concentrate and B concentrate [1] - A concentrate includes sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2.2H2O), magnesium chloride (MgCl2.6H2O), acetic acid (CH3COOH), and dialysis water [1] - B concentrate is composed of sodium bicarbonate (NaHCO3) and dialysis water [1] Group 2: Application Scope - The product is intended for use in the treatment of acute renal failure and chronic renal failure through blood dialysis [1]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-079 甘肃陇神戎发药业股份有限公司 关于获得血液透析浓缩液医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 注册人名称：甘肃陇神戎发药业股份有限公司 注册人住所及生产地址：甘肃省兰州市榆中县定远镇国防路 10 号 产品名称：血液透析浓缩液 型号、规格： | 型号 | 组成 | 规格 | 装量 | | --- | --- | --- | --- | | LS-Y1 | A 浓缩液 | A1 | 5L | | | | A2 | 10L | | | B 浓缩液 | B1 | 6L | | | | B2 | 12L | 结构及组成：血液透析浓缩液由 A 浓缩液和 B 浓缩液两部分组成。A 浓缩液 由氯化钠（NaCl）、氯化钾（KCl）、氯化钙（CaCl2·2H2O）、氯化镁（MgCl2·6H2O）、 冰醋酸（CH3COOH）及透析用水组成，B 浓缩液由碳酸氢钠（NaHCO3）和透析用 水组成。 适用范围：用于急性肾衰竭、慢性肾衰竭的血液透析治疗。 生效日期：二〇二五年十一月二十八日 ...

证券日报网讯 11月20日晚间，陇神戎发发布公告称，公司控股子公司甘肃普安制药股份有限公司因 《药品生产许可证》有效期即将届满而提前办理了换证手续，于近日收到由甘肃省药品监督管理局核准 换发的《药品生产许可证》。 （编辑 楚丽君） ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

证券代码：300534 证券简称：陇神戎发 公告编号：2025-078 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品生产许可证》的公告 企业负责人：王明宏 质量负责人：陈双明 生产地址和生产范围：甘肃省武威市凉州区黄羊生态工业（食品）示范园农 大北路 1 号：合剂，膜剂，原料药（盐酸纳洛酮），前处理、提取*** 有效期至：2030 年 11 月 13 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）因《药品生产许可证》有效期即将 届满而提前办理了换证手续，于近日收到由甘肃省药品监督管理局核准换发的 《药品生产许可证》，现将有关情况公告如下： 一、换发后的《药品生产许可证》基本信息 企业名称：甘肃普安制药股份有限公司 社会信用代码：91620600762352467T 注册地址：甘肃省武威市凉州区黄羊生态工业（食品）示范园农大北路 1 号 法定代表人：王明宏 特此公告。 甘肃陇神戎发药业股份有限公司董事会 许可证编号：甘 201600 ...

Core Viewpoint - The company is focusing on its main business while expanding its product offerings in traditional Chinese medicine, particularly in the herbal medicine segment [1] Group 1: Company Strategy - The company is actively selling its main products, including Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, while also developing its herbal medicine business [1] - The company has not yet participated in centralized procurement for its herbal medicine products and is monitoring related policies and market dynamics [1] Group 2: Market Positioning - The company aims to align its herbal medicine business with market demand and its strategic planning to create value for itself and its shareholders [1]

Core Insights - The company is focusing on its main business while actively expanding its traditional Chinese medicine (TCM) decoction pieces segment to enrich its product structure [1] - The company has not yet participated in the centralized procurement (集采) for TCM decoction pieces and will continue to monitor procurement policies and market demand [1] Group 1 - The company is currently selling key products such as Yuanhu Zhitong Droplets and Xuanfei Zhiso Mixture while developing its TCM decoction pieces business [1] - The centralized procurement policy has expanded to include 86 varieties of TCM decoction pieces, indicating a growing market scale and increasing importance among listed companies [3] - The company aims to create value for itself and its shareholders through a strategic layout in the TCM decoction pieces market [1]

Core Viewpoint - The stock of Longshen Rongfa has shown a mixed performance with a year-to-date increase of 22.06%, but a recent decline over the past 60 days, indicating potential volatility in the market [1]. Financial Performance - For the period from January to September 2025, Longshen Rongfa reported a revenue of 647 million yuan, representing a year-on-year decrease of 19.71%. However, the net profit attributable to shareholders increased by 9.13% to 27.03 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 42.64 million yuan, with 24.27 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, the number of shareholders for Longshen Rongfa decreased by 2.52% to 27,100, while the average number of tradable shares per shareholder increased by 2.59% to 11,147 shares [2]. - The fifth largest circulating shareholder is Huatai-PB Asset Management's Zhongzheng Traditional Chinese Medicine ETF, which holds 1.33 million shares, an increase of 351,800 shares compared to the previous period [3]. Market Activity - On November 11, the stock price of Longshen Rongfa rose by 2.13% to 10.57 yuan per share, with a trading volume of 65.20 million yuan and a turnover rate of 2.07%. The total market capitalization stands at 3.206 billion yuan [1]. - The net inflow of main funds was 2.31 million yuan, with significant buying activity from large orders [1]. Business Overview - Longshen Rongfa, established on June 3, 2002, and listed on September 13, 2016, primarily engages in the production and sales of traditional Chinese medicine, with 86.53% of its revenue derived from pharmaceutical sales [1]. - The company operates within the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [1].

Core Insights - Longshen Rongfa has received the Medical Device Registration Certificate for its blood dialysis powder, marking its entry into the medical device sector and filling a market gap in the northwest region of China [1][2] Company Developments - The product's registration certificate is valid from November 5, 2025, to November 4, 2030, indicating a long-term commitment to the medical device market [1] - Longshen Rongfa is the first company in the northwest provinces of Gansu, Qinghai, Ningxia, and Xinjiang to successfully obtain this registration, enhancing its competitive position [1] - The blood dialysis powder is designed for both acute and chronic renal failure treatments and is compatible with various brands of dialysis machines, addressing a wide range of patient needs [1] Market Potential - According to the Chinese Medical Association, the total number of dialysis patients in mainland China is projected to reach 1.183 million in 2024, with 1.027 million undergoing blood dialysis, indicating a growing market for dialysis-related products [2] - The company is also advancing the construction of production lines and obtaining production licenses for related products, including blood dialysis concentrates, which will further expand its product offerings and revenue streams [2] - The anticipated launch of these products is expected to create new profit growth points and support the company's long-term development strategy [2]